What is Sermorelin?

A lab-made copy of the active front part of the body's own growth-hormone-releasing hormone, originally made as an injectable prescription drug.

At a glance

What it is
A lab-made copy of the active front part of the body's own growth-hormone-releasing hormone, originally made as an injectable prescription drug.
Also called
GRF 1-29 NH2 · GHRH (1-29) amide · GRF(1-29)
US status
503A basis to verifyPharmacies compound it, but FDA has not confirmed the basis a 503A pharmacy relies on.
Evidence
C: Small or uncontrolled human dataSmall, short human studies that mostly measured hormone levels, for the adult wellness, "anti-aging" and body-composition uses that programs sell.
Safety signal
Well characterizedThe old approved product (GEREF), at labeled pediatric dosesNo data (unknown ≠ safe)Compounded oral, ODT, troche or long-term adult wellness use

Status checked Nov 16, 2026 · To verify

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Randomized controlled trials43Measured: growth rate and IGF-1 in 43 children randomized to one of three arms, growth hormone among them, with GHRH(1-29)-NH2 for 6 months (Neyzi 1993).39
Controlled studies19Measured: growth hormone over 24 hours, IGF-1, glucose and baseline testosterone in 10 older men (mean age 68) and 9 young men given GHRH(1-29) at two strengths for 14 days each, in random order, with no placebo (Corpas 1992).37
Controlled studies19Measured: growth hormone, IGF-1, body composition by DEXA, skin, insulin sensitivity and quality of life, sleep included, in 19 adults aged 55 to 71 (10 women, 9 men) given [Nle27]GHRH(1-29), an analogue, not sermorelin, for 16 weeks after 4 weeks of single-blind placebo (Khorram 1997a).38
Controlled studies19Measured: immune markers in the same 19 adults given the same analogue, not sermorelin, for 16 weeks (Khorram 1997b).19

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Controlled studies13Measured: sleep EEG, growth hormone and cortisol in 13 older adults (5 women, mean age 69) given GHRH by IV or placebo on single nights; the abstract does not say which GHRH (Guldner 1997).47
Controlled studies89Measured: cognition in 89 older men and women given "GHRH" or placebo for 6 months; the abstract does not name the exact molecule (Vitiello 2006).4951
Open-label studies11Measured: growth hormone, IGF-1, strength, body composition by DEXA and muscle by NMR in 11 men aged 64 to 76 given GHRH 1-29 for 6 weeks, in an open-label study with no control group (Vittone 1997).18
Open-label studies110Measured: growth rate, bone age and safety in 110 children (86 analyzed) given GHRH(1-29) for up to 12 months, in an open-label study at several centers by the GEREF study group (Thorner 1996).35
Observational studies14Measured: IGF-1, testosterone, LH and FSH in 14 of 105 men (mean age 33) already on testosterone, given sermorelin with GHRP-2 and GHRP-6 for a mean of 134 days, in a look back at their charts with no control group (Sigalos 2017).46
Case reports and series2Measured: sleep EEG in 2 older men given GHRH over about 28 days, in a case series (Murck 1997).48
Registered trialsNot statedRegistered trial NCT00000380 of GHRH for sleep problems linked to age, completed (1996 to 2007); the record does not name the molecule as sermorelin.51
Registered trials13Registered trial NCT01410799 of GHRH for 3 months in older adults, terminated; the record does not name the molecule as sermorelin.51
Registered trials5Registered trial NCT00807365 of GHRH for 6 months in older adults, terminated; the record does not name the molecule as sermorelin.51
Registered trials3Registered trial NCT00791843 of GHRH in heart failure, completed; the record does not name the molecule as sermorelin.51
Registered trials22Registered trial NCT02553603 of GHRH in mild cognitive impairment, completed; the record does not name the molecule as sermorelin.51
Registered trials60Registered trial NCT00675506 of GHRH 1-44 for belly fat in obesity, completed; the record does not name the molecule as sermorelin.51
Reviews435Measured: growth hormone response to IV sermorelin plus arginine, as a diagnostic test, in 2 studies from Italy (1996, 435 patients in total), the only eligible studies an FDA-funded M-CERSI review found; it found no US study and no study of compounded sermorelin.11

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Stimulates natural GH productionIts pharmacology and small human studies show that growth hormone release rises: a hormone level, not an outcome a person feels.121819C
Raises / "restores" IGF-1Mixed: IGF-1 rose 28% in a study of 19 people given an analogue, not sermorelin, and did not change in a study of 11 men.1819C
Better sleepWe found no sermorelin trial that measured sleep outcomes.F
Lean muscle / strengthOne open-label study of 11 men found a change in 2 of 6 strength measures, and no change in lean mass.18C

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Fat loss / metabolismA study of 11 men found no change in body fat on a DEXA scan. We found no randomized trial of sermorelin for weight loss.1118F
Energy / vitality / mental clarityWe found no human study.F
Skin, hair, nailsWe found no human study.F
RecoveryWe found no human study.F
Immune supportA study of 19 people given an analogue, not sermorelin, found changes in immune markers.19C
"Safer / more natural than HGH"We found no study that compares the safety of sermorelin and HGH head to head.F
"FDA-approved peptide"Not true today: GEREF, the only approved sermorelin drug, was discontinued, and compounded sermorelin is not FDA-approved.1Contradicted
Treats pediatric GHD / diagnostic testThe FDA approved GEREF for these uses; the approvals have since been withdrawn.1A

Safety facts

On the FDA label

  • The GEREF label listed a reaction where the drug was injected (pain, swelling or redness) as the most common, in about 1 in 6 patients. 3 of 350 patients stopped because of it.1213
  • The GEREF label listed headache, flushing, trouble swallowing (dysphagia), dizziness, hyperactivity, sleepiness (somnolence) and hives (urticaria), each in under 1% of patients.12
  • The GEREF label reported hypothyroidism in 6.5% of patients in trials, and advised thyroid tests before and during treatment.1213
  • The GEREF label said many patients developed antibodies to GRF, of unclear significance, and that allergic reactions were possible.12
  • The GEREF label said the drug was not studied in growth hormone deficiency caused by a lesion inside the skull, and placed it in Pregnancy Category C (the old system). Whether it passes into breast milk is not known.1213
  • The GEREF label said IGF-1, growth hormone, phosphorus and alkaline phosphatase may rise, and that a physician experienced in growth hormone deficiency was to supervise treatment.12
  • The label information gives a half-life of about 11 to 12 minutes. About 6% of the drug injected under the skin reaches the bloodstream.13

Reports to the FDA

  • The FDA's adverse event database (FAERS, updated October 28, 2026) holds 69 reports that mention sermorelin. The most frequent terms include itching (pruritus), trouble swallowing, hypersensitivity, nausea and anaphylactic reaction (4 reports); the reports are not checked, and they do not show that sermorelin caused the event.14
  • Sleepiness (somnolence) is listed in under 1% of patients on the GEREF label, and appears in 1 FAERS report.1252
  • Hair loss is not on the GEREF label's list of adverse reactions. None of the 183 reaction terms in the FAERS reports on sermorelin is alopecia.1252
  • Of the FAERS reports on sermorelin, 45 are coded as serious and 24 as not serious.52
  • In FAERS, 41 reports on sermorelin are coded as from the US, and the rest are not.52
  • None of the 183 reaction terms in the FAERS reports on sermorelin is a neoplasm, cancer, carcinoma, tumor or lymphoma.52

What the FDA has said

  • The FDA states that compounded drugs are "not FDA-approved". Empower Pharmacy's own page says its products are not tested by the FDA for safety or efficacy.526

No data

  • We found no data on adults who take it long term for wellness, on pregnancy or breastfeeding, on forms taken by mouth (oral, ODT or troche), on people with a history of cancer, or on combination products.1112
  • The cancer warnings on the labels of other growth-hormone drugs are not about sermorelin. We found no FDA or NIH statement on sermorelin and cancer.

Product quality

  • The FDA found "research use only" sermorelin sold for human use and treated it as an unapproved new drug. We found no contamination or potency test data for compounded sermorelin.10

Compounded sermorelin is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Names the pharmacy that fills it: a state-licensed 503A pharmacy, for one patient's prescription, or an FDA-registered 503B outsourcing facilityLegalGood practice
  • Does not call its compounded sermorelin "FDA-approved", describes GEREF as discontinued if it mentions it, and does not present "FDA-registered" as approvalLegal
  • Orders lab tests before and during treatment, such as IGF-1 and thyroid function, since the old label reported hypothyroidismGood practice
  • Warns athletes that WADA prohibits sermorelin at all times15Good practice
  • Requires a prescription, after an evaluation by a prescriber licensed in your stateLegal
  • Uses a pharmacy licensed or permitted to ship to your state, with a license you can look upLegal
  • Does not sell it as "research use only" or "not for human consumption", which the FDA treats as an unapproved drug sale10Legal
  • Gets the active ingredient from an FDA-registered manufacturer with a valid certificate of analysis (COA), and can show the COA or third-party potency, sterility and endotoxin tests on request5LegalGood practice
  • Sells single-ingredient sermorelin, or names every active ingredient in a blend (blends with GHRP-2 or GHRP-6 are unstudied)11Good practice
  • Lists side effects and who should not take it, including injection reactions, thyroid effects and allergyGood practice
  • Shows prices, auto-renewal terms, and the cancellation and refund policy before checkoutLegalGood practice
  • Tells patients how to report a side effect to the FDA (MedWatch)Good practice
  • Keeps claims about benefits limited and never "guaranteed", with no testimonials about other drugsGood practice

  1. 1.
  2. 2.
    DrugFuture mirror of Drugs@FDA, GEREF recordsTier 1: regulator or registerdrugfuture.comread Nov 16, 2026↩
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
    FDA, PCAC meeting notice, July 23-24 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  10. 10.
    FDA Warning Letter, Xcel Research LLC, MARCS-CMS 694608 (2024-12-10)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  11. 11.
    University of Maryland M-CERSI, "Summary Report: Sermorelin Acetate" (Dec 2020, FDA grant 5U01FD005946)Tier 2: peer-reviewed or trial registryarchive.hshsl.umaryland.eduread Nov 16, 2026↩
  12. 12.
    RxList, Sermorelin Acetate (label-derived; side effects and description)Tier 3: reference, law firm or pressrxlist.comread Nov 16, 2026↩
  13. 13.
    RxList, Sermorelin Acetate clinical pharmacologyTier 3: reference, law firm or pressrxlist.comread Nov 16, 2026↩
  14. 14.
  15. 15.
    WADA Prohibited List (2026), S2.2.4Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
  16. 16.
    German Sport University Cologne, S2 prohibited class pageTier 3: reference, law firm or pressdshs-koeln.deread Nov 16, 2026↩
  17. 17.
    DEA Diversion, Controlled Substances, Alphabetical Order (footer 12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  18. 18.
  19. 19.
    Khorram O et al., JCEM 1997 (Nov), [Nle27]GHRH(1-29)-NH2 in aging men and women (via QxMD)Tier 2: peer-reviewed or trial registryread.qxmd.comread Nov 16, 2026↩
  20. 20.
    Walker RF, "Sermorelin: a better approach…?" Clin Interv Aging 2006;1(4):307-8 (editorial)Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026
  21. 21.
    Frier Levitt, "FL Peptides" (Jan 2026)Tier 3: reference, law firm or pressfrierlevitt.comread Nov 16, 2026
  22. 22.
    Portrait Care, "Is Sermorelin FDA Approved?"Tier 4: lead onlyportraitcare.comread Nov 16, 2026
  23. 23.
    Strut Health, Sermorelin pageTier 4: lead onlystruthealth.comread Nov 16, 2026
  24. 24.
    Bodybuilding Health+ (Dynamo Group LLC), Sermorelin pageTier 4: lead onlybbhealthplus.comread Nov 16, 2026
  25. 25.
    Invigor Medical, Sermorelin checkoutTier 4: lead onlytryinvigor.comread Nov 16, 2026
  26. 26.
    Empower Pharmacy, Sermorelin pageTier 4: lead onlyempowerpharmacy.comread Nov 16, 2026↩
  27. 27.
    HealingMaps, "Sermorelin is the FDA-Approved Peptide…"Tier 4: lead onlyhealingmaps.comread Nov 16, 2026
  28. 28.
    HealingMaps, "The 4 Best Sermorelin Programs Online in 2026"Tier 4: lead onlyhealingmaps.comread Nov 16, 2026
  29. 29.
  30. 30.
    Drugs@FDA, NDA 020443 overview (GEREF)Tier 1: regulator or registerFDAread Nov 16, 2026
  31. 31.
    Drugs@FDA, NDA 019863 overview (GEREF)Tier 1: regulator or registerFDAread Nov 16, 2026
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
  55. 55.
  56. 56.
    FDA supplement approval letter BLA 022505/S-020, Egrifta WR (2025-03-25)Tier 1: regulator or registerFDAread Nov 16, 2026
  57. 57.
    EGRIFTA (2 mg/vial) label, BLA 022505 S-010 ("Revised: 11/2018")Tier 1: regulator or registerFDAread Nov 16, 2026
  58. 58.
  59. 59.
  60. 60.
  61. 61.
    USADA, "Athlete Advisory: What's New on the 2027 WADA Prohibited List?"Tier 1: regulator or registerUSADAread Nov 16, 2026
  62. 62.
  63. 63.
  64. 64.
  65. 65.

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.